In brief
In a surprising move, Trump is threatening Denmark with tariffs if they don't hand over Greenland. This could impact beloved American products like Ozempic, manufactured by Denmark's Novo Nordisk, raising concerns about availability and prices.
President-elect Donald Trump has unveiled a bold economic proposal: he plans to impose hefty tariffs on Denmark unless the country agrees to cede Greenland, an autonomous territory. He claims the island is vital for national security and suggests it should be integrated into the United States.Despite Denmark being a small trading partner, sending only an $11 billion slice of goods to the U.S. in 2023, the repercussions of such tariffs could be significant. Many popular American products come from Denmark, especially medical supplies. Nearly half of Denmark's exports to the U.S. are made up of critical packaged medicines, including insulin, vaccines, and antibiotics.The prime culprit? Novo Nordisk, a major Danish pharmaceutical company that manufactures popular weight-loss drugs like Ozempic and Wegovy. The drugmaker is closely linked to Denmark's economy, recently driving half of its private sector job growth. As Novo Nordisk ramps up its U.S. production to meet skyrocketing demand, the uncertainty brought by potential tariffs could threaten overall access to these essential medications.Novo Nordisk confirmed they are monitoring the situation but refrained from commenting on any potential impact. If Trump's tariffs go through, U.S. consumers might face much higher prices for these vital products, raising concerns about healthcare access and affordability.
